Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00338182 | AZD1152 in Patients With Advanced Solid Malignancies | PHASE1 | COMPLETED | 43 | — | — | May 23, 2006 | Mar 1, 2017 | Apr 24, 2017 | 2 | United States |
Safety and tolerability will be assessed through the incidence of adverse events. Adverse events will include significant findings on vital signs, clinical chemistry/haematology, coagulation parameters and electrocardiograms (ECGs).
| Arm | Type | Description |
|---|---|---|
| AZD1152 | EXPERIMENTAL | AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment) |
| Name | Type | Description |
|---|---|---|
| AZD1152 part A | DRUG | 48-hour continuous intravenous infusion |
| AZD1152 part B | DRUG | 2-hour intravenous infusion |
Inclusion Criteria: * Histological or cytological confirmation of a solid, malignant tumour * At least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Exclusion Criteria: * Participation in an investigational drug stud...